The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice

Current Controlled Trials in Cardiovascular Medicine

Volumn 3, Issue , 2002, Pages

  Aronow, Herbert D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

HMG CoA; Myocardial infarction; Myocardial ischemia; Reductase inhibitors; Unstable angina

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN; TIROFIBAN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL OBSERVATION; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; DRUG SAFETY; DRUG UTILIZATION; HEART DEATH; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; RESUSCITATION; RISK REDUCTION; SUDDEN DEATH;

EID: 16344373690     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-3-3     Document Type: Article

References (30)

1. The 4S Investigators: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389
2. The LIPID Investigators: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349-1357
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009
4. HPS Investigators: MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999, 20:725-741
5. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718
6. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001, 357:1063-1068
7. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001, 285:430-436
8. Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG: Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1998, 81:578-581
9. Flaker GC, Warnica JW, Sacks FM, Moye LA, Davis BR, Rouleau JL, Webel RR, Pfeffer MA, Braunwald E: Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol 1999, 34:106-112
10. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999, 20:58-69
11. Christenson JT: Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease. Am J Cardiol 2001, 88:896-869
12. The FRISC II Investigators: Invasive compared with non invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Lancet 1999, 354:708-715
13. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001, 344:1879-1887
14. Solomon DH, Stone PH, Glynn RJ, Ganz DA, Gibson CM, Tracy R, Avorn J: Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol 2001, 38:969-976
15. Szucs TD, Meyer BJ, Kiowski W: Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. Eur Heart J 1999, 20:1253-1260
16. Mark DB, Harrington RA, Lincoff AM, Califf RM, Nelson CL, Tsiatis AA, Buell H, Mahaffey KW, Davidson-Ray L, Topol EJ: Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000, 101:366-371
17. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, Steward DE, Theroux P, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000, 36:970-1062
18. Cambou JP, Grenier O, Ferrieres J, Danchin N: Secondary prevention of patients with acute coronary syndrome in France. The Lancet Conference 1999, Copenhagen. Abstracts book 75
19. Muhlestein JB, Home BD, Bair TL, Li Q, Madsen TE, Pearson RR, Anderson JL: Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001, 87:257-261
20. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH: Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol 2001, 87:819-822
21. Aronow HD, Novaro GM, Prosper DM, Lincoff AM, Topol EJ, Nissen SE: Initiation of lipid-lowering therapy during hospitalization for coronary intervention is a powerful predictor of subsequent compliance (abstract). Eur Heart J 2001, 22:271
22. Wattanasuwan N, Khan IA, Gowda RM, Vasavada BC, Sacchi TJ: Effect of acute myocardial infarction on cholesterol ratios. Chest 2001, 120:1196-1199
23. DeBusk RF, Miller NH, Superko HR, Dennis CA, Thomas RJ, Lew HT, Berger WE 3rd, Heller RS, Rompf J, Gee D, et al: A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Interm Med 1994, 120:721-729
24. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley, S: Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA 1997, 277:1281-1286
25. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459-467
26. Executive Summary of The Third Report of The National Cholesterol Education Program. (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497
27. EUROASPIRE I and II Group: Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries, Lancet 2001, 357:995-1001
28. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA: of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction Circulation 2001, 103:38-44
29. Gotto AM Jr: Ongoing clinical trials of statins. Am J Cardiol 2001, 88:36F-40F
30. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers J: Simvastatin at niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592